PDS Biotech's HPV16 Cancer Therapy Shows 39-Month Survival in Phase 2 Trial
Event summary
- PDS Biotech published Phase 2 trial results in JAMA Oncology showing 39.3-month median overall survival for HPV16-positive head and neck cancer patients treated with PDS0101 and pembrolizumab.
- The trial reported a 36% objective response rate, significantly higher than the 19% seen with standard pembrolizumab treatment.
- PDS Biotech secured $22.3 million in PIPE financing led by Nant Capital and is exploring a licensing deal for PDS0101.
- The company will prioritize PDS0301 for metastatic colorectal cancer while pursuing partnerships for PDS0101.
The big picture
PDS Biotech's Phase 2 trial results position PDS0101 as a potential breakthrough in HPV16-positive head and neck cancer treatment, offering a significant survival advantage over current standards. The company's strategic shift to prioritize PDS0301 for metastatic colorectal cancer reflects a targeted approach to high-unmet-need indications. The recent financing and potential licensing deal underscore the growing interest in PDS Biotech's immunotherapy platform.
What we're watching
- Partnership Strategy
- Whether PDS Biotech can secure a favorable licensing deal for PDS0101 within the one-year exclusive negotiation period with NantWorks.
- Clinical Development
- The pace at which PDS0301 advances in metastatic colorectal cancer and other solid tumors.
- Market Positioning
- How the durable survival outcomes of PDS0101 will position the company in the competitive landscape of HPV16-targeted therapies.
Related topics